title: [Clinical and laboratory efficacy of the novel difluoroquinolone Sparflo (sparfloxacin) in therapy of skin and soft tissue infections].
abstract: Results of clinical trial of new difluoroquinolone--Sparflo (sparfloxacin, Dr. Reddy's Laboratories Ltd) are presented. Sparfloxacin was used in the treatment of 24 patients at the Department of Wounds and Wounds infections (11 patients) and at the Department of burn wounds (13 patients) of the A.V. Vishnevsky Institute of Surgery. After the treatment with sparfloxacin pathogen eradication was stated in 18 patients, eradication with superinfection--in 13 patients, persistence--in 3 patients. Thus bacteriological efficacy amounted to 87.5 per cent. Pharmacokinetic data demonstrates long-term sparfloxacin circulation in the organism of patients with burns--elimination half-life amounted to 20 hours. Overall after the sparfloxacin use the favourable clinical effect was stated in 100 per cent patients--18 patients (75%) had clinical cure and 6 (25%)--clinical improvement. The drug tolerance was good. It is concluded that clinical and laboratory investigation demonstrated high efficacy of sparfloxacin (Sparflo, Dr. Reddy's Laboratories Ltd) in the treatment of patients with skin and tissue wounds of different localization and genesis, complicated with infections.
authors.affiliation: A.V. Vishnevsky Institute of Surgery, Russian Academy of Medical Sciences, Moscow.
authors.forename: V P
authors.initials: VP
authors.lastname: Iakovlev
authors.forename: M G
authors.initials: MG
authors.lastname: Krutikov
authors.forename: L A
authors.initials: LA
authors.lastname: Blatun
authors.forename: G N
authors.initials: GN
authors.lastname: Izotova
authors.forename: I A
authors.initials: IA
authors.lastname: Grishina
mesh_terms: D000150:Acinetobacter / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002056:Burns / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D011513:Proteus mirabilis / Q000187:drug effects; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C061363:sparfloxacin
vernacular_title: Kliniko-laboratornaia éffektivnost' novogo diftorokhinolona Sparflo (sparfloksatsina) pri lechenii infektsiĭ kozhi i miagkikh tkaneĭ.